Cara Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview

Tvardi Therapeutics

01/03/2024 21:16

* Cara Therapeutics Inc  CARA.OQ   CARA.O  is expected
to show a
rise in quarterly revenue when it reports  results on March 4
for the period ending December 31 2023
    * The Stamford Connecticut-based  company is expected to
report a
188.9% increase in revenue to $9.421 million from $3.26 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Cara Therapeutics Inc is
for a
loss of 41 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cara
Therapeutics
Inc is $5.00​, above​ its last closing price of $0.85. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.53       -0.52      -0.52     Met     0
 Jun. 30 2023  -0.53       -0.54      -0.58     Missed  -7.7
 Mar. 31 2023  -0.51       -0.52      -0.49     Beat    6​
 Dec. 31 2022  -0.35       -0.32      -0.56     Missed  -75
 ​​Sep.        -0.43       -0.42      -0.43     Missed  -2.7
 30 2022                                                
 Jun. 30 2022  -0.25       -0.25      -0.08     Beat    68.4​
 Mar. 31 2022  -0.54       -0.54      -0.52     Beat    3.1
 Dec. 31 2021  -0.50       -0.52      -0.63     Missed  -22.2
 This summary was machine generated March 1 at 21:16 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)